Yahoo · Sep 22, 2026
Can Pediatrix Sustain Growth Despite Lower Patient Volumes?
MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.
NYSE · MD
Healthcare · Medical - Care Facilities
$26.92
Up+$0.28 (+1.05%)
Updated Oct 13, 2026, 3:23 AM
SID Score
7.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
MD closed at $26.92 after 21 trading sessions, up 0.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $26.64 | $27.04 | $26.56 | $26.92 | 487.33K |
| Oct 9, 2026 | $26.35 | $26.86 | $26.33 | $26.64 | 518.04K |
| Oct 8, 2026 | $25.70 | $26.35 | $25.54 | $26.24 | 729.99K |
| Oct 7, 2026 | $25.81 | $26.40 | $25.72 | $25.83 | 655.82K |
| Oct 6, 2026 | $26.27 | $26.51 | $25.70 | $26.00 | 667.75K |
| Oct 5, 2026 | $25.90 | $26.46 | $25.5901 | $26.10 | 953.19K |
| Oct 2, 2026 | $25.77 | $26.2928 | $25.67 | $25.97 | 616.42K |
| Oct 1, 2026 | $25.80 | $26.1168 | $25.40 | $25.76 | 1.53M |
| Sep 30, 2026 | $26.14 | $26.51 | $25.64 | $25.73 | 779.5K |
| Sep 29, 2026 | $25.82 | $26.10 | $25.4801 | $26.06 | 528.31K |
| Sep 28, 2026 | $26.23 | $26.82 | $25.85 | $25.93 | 629.32K |
| Sep 25, 2026 | $25.66 | $26.34 | $25.66 | $26.31 | 386.03K |
| Sep 24, 2026 | $26.25 | $26.25 | $25.55 | $25.66 | 732.59K |
| Sep 23, 2026 | $26.23 | $26.40 | $25.79 | $25.86 | 454.01K |
| Sep 22, 2026 | $25.61 | $26.485 | $25.61 | $26.35 | 817.97K |
| Sep 21, 2026 | $26.06 | $26.06 | $25.30 | $25.77 | 506.76K |
| Sep 18, 2026 | $25.50 | $25.97 | $25.1801 | $25.93 | 2.06M |
| Sep 17, 2026 | $26.36 | $26.47 | $25.49 | $25.49 | 856.56K |
| Sep 16, 2026 | $26.94 | $27.22 | $26.06 | $26.13 | 629.32K |
| Sep 15, 2026 | $26.61 | $27.219 | $26.20 | $26.69 | 804.39K |
| Sep 14, 2026 | $26.98 | $27.33 | $26.05 | $26.91 | 754.21K |
The latest Smart Investors Daily articles mentioning MD.
Company
Market Activity
Research & News
MD research
Company profile and research snapshot.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Jefferies | Hold | — |
| Aug 6, 2026 | UBS | Neutral | — |
| Jul 14, 2026 | Truist Securities | Hold | — |
| May 12, 2026 | UBS | Neutral | — |
| Apr 13, 2026 | Truist Securities | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 22, 2026
MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.
Yahoo · Sep 21, 2026
Pediatrix Medical Group (MD) has drawn fresh attention after trading around a recent close of US$25.93. Investors are weighing this level against the company’s longer term return record and its current healthcare services footprint. Recent trading has been choppy for Pediatrix Medical Group, with a 1-day share price return of 1.73% offsetting some of the pressure from a 7-day share price return that slipped 3.64%. At the same time, the year-to-date share price return of 21.79% and a 1-year...
Yahoo · Sep 18, 2026
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Yahoo · Sep 16, 2026
On August 4, Pediatrix Medical Group (NYSE:MD) reported second-quarter results that look strong on the surface. Adjusted earnings per share jumped to $0.63 from $0.53, and net revenue grew to $487.8 million. But look past the headline numbers, and the growth is coming largely from pricing and a shrinking share count, not from more patients […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning MD.